acamprosate vs entacapone
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and entacapone. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Comtan
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Entacapone is a medicine that helps people with Parkinson's disease. It is always used with levodopa and carbidopa to help reduce "wearing-off" symptoms.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Entacapone is used to treat Parkinson's disease. It helps when your medicine (levodopa and carbidopa) starts to wear off before your next dose. This medicine is not for people with Parkinson's who do not have "wearing-off" symptoms.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Entacapone belongs to a class of drugs called COMT inhibitors. It works by blocking an enzyme called COMT, which breaks down levodopa in the body. By blocking COMT, entacapone helps levodopa work longer and more effectively.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Uncontrolled movements
- • Urine discoloration
- • Diarrhea
- • Nausea
- • Excessive movements
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Dyskinesia 461
- Hallucination 459
- Fall 443
- Death 318
- Parkinson^S Disease 274
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
If you suddenly stop taking entacapone or quickly lower the dose, your Parkinson's symptoms may get worse. This could also cause a high fever and confusion. If you stop taking entacapone, your doctor should watch you closely and adjust your other medicines as needed. It is best to slowly lower the dose before stopping completely.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if entacapone will harm your unborn baby. Talk to your doctor about the risks and benefits of taking entacapone while breastfeeding.
How to Read This acamprosate vs entacapone Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while entacapone sits within the COMT Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while entacapone has 1,955. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or entacapone.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.